+1.650.627.4531 inquiry@medeortx.com
Contact Us| Find us on:

Board of Directors

 

 

CHIH PING (CP) LIU, PH.D.

CHAIRMAN OF THE BOARD

CP Liu, PhD is a co-founder of Medeor. Dr. Liu has co-founded Bolt Biotherapeutics and Tranquis Therapeutics. He founded Pepgen Corporation where he was a corporate executive. Dr. Liu was the co-founder of General Biologicals Corporation and the president and Chief Executive Officer. He joined Han Ding Ventures and Champion Consulting Group in Taiwan as an investment specialist in early stage investments.

Dr. Liu holds a PhD in genetics from the University of Wisconsin-Madison. Dr. Liu continued his education as a postdoctoral fellow at Yale University in cellular biology, then continuing at the University of Wisconsin-Madison in molecular immunology and lastly at UC Berkeley in molecular biology. We believe that Dr. Liu is qualified to serve on the board because of his extensive professional experiences including investment, founding and leading companies.

 


 

Frank Kung, Ph.D., MBA

Board Member

Frank Kung, Ph.D., M.B.A. has served on our Board since October 2013. He is a founding member and managing partner of Vivo Capital, LLC, a healthcare and biotechnology private equity investment firm established in 1996. In 1984, he co-founded Genelabs Technologies, Inc., where he served as Chairman and CEO until 1995. He previously co-founded Cetus Immune Corporation in 1981, a majority owned subsidiary of Cetus, which was acquired by its parent in 1983. Dr. Kung started his career in the biotechnology industry when he joined Cetus Corporation in 1979.

Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan and his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. Dr. Kung currently serves on the board of directors of Amyris, Inc., a publicly-traded biotechnology company, as well as on the board of TOT Biopharm Company Ltd., a privately held biotechnology company. We believe that Dr. Kung is qualified to serve on our Board because of his extensive experience in the life sciences industry, his service on the boards of directors of other life sciences companies and his investing experience.

 


 

Wei Li, Ph.D., MBA

Board Member

Dr. Wei Li has served on our board since September 2015. Dr. Li is a Founding Partner of WuXi Healthcare Ventures and Managing Partner of 6 Dimensions Capital. Prior to joining WuXi Healthcare Ventures, Dr. Li focused his efforts on healthcare and life science investment opportunities at Fidelity Biosciences, Fidelity Growth Partners Asia, and Baird Venture Partners. He also led drug discovery projects and technology licensing due diligence at Vertex Pharmaceuticals, a global biotechnology company located in Boston, MA. During his scientific research career, Dr. Li first-authored numerous scientific publications in journals including Science, Proceedings of the National Academy of Sciences (PNAS), and the Journal of Biological Chemistry.

Dr. Li received a BS, with distinction, in Chemical Physics from the University of Science and Technology of China, a PhD in Biochemistry and Mammalian Genetics from Harvard University, and an MBA with a concentration in Finance, Accounting and Marketing from the Kellogg School of Management at Northwestern University, where he was elected to Beta Gamma Sigma, the academic business honor society. We believe that Dr. Li is qualified to serve on our Board because of his extensive experience in the life sciences industry, his service on the boards of directors of other life sciences companies and his extensive investing experience.